CINGW — Cingulate Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1862150 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -7,490,660 -7,731,397 28,150,677 23,185,900 7,383,547
Jun 2026 0 — -5,414,975 -5,870,264 33,066,321 28,402,819 9,599,286
Mar 2026 0 — -7,923,318 -9,312,089 30,861,701 25,893,210 11,996,835
Dec 2025 0 — -5,585,948 -6,272,910 15,073,263 10,953,383 12,564,356

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-20,654,108
Investing CF
$-284,476
Financing CF
$40,441,220
CapEx
$-284,476
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-147,557,384
Inventory
—
Receivables
$38,447
ST Investments
—
EBIT TTM
$-24,919,785
Pretax Income TTM
$-28,796,325
Interest Exp TTM
—
Analysts
—

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -19,938,057 -22,449,911 15,073,263 12,564,356 2,508,907 -17,245,182
Dec 2024 0 -15,645,265 -16,559,605 14,864,489 7,408,984 7,455,505 -18,451,387
Dec 2023 0 -22,759,304 -23,534,947 3,491,436 10,360,865 -6,869,429 -15,034,543
Dec 2022 0 -17,502,280 -17,676,232 11,405,057 7,523,035 3,882,022 -15,882,808

TTM Snapshot

Revenues TTM
$3,502,172
NetIncome TTM
$-29,040,838
OpCashFlow TTM
—
Assets (Latest)
$33,066,321
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
LLY ELI LILLY & Co $1.26T $1415.55 —
JNJ JOHNSON & JOHNSON $670.92B $278.70 —
ABBV AbbVie Inc. $517.59B $292.82 —
MRK Merck & Co., Inc. $353.44B $143.37 —
NVS NOVARTIS AG $302.46B $159.13 —

News headlines (Yahoo Finance, 1h cache)

Cingulate Issued First U.S. Patent for Lead ADHD Asset CTx-1301
2026-06-16 12:00 · Yahoo
Cingulate Inc. Reports Third Quarter 2026 Financial Results and Provides Regulatory Update on CTx-1301 NDA Resubmission
2026-11-13 21:45 · Yahoo
Shane Schaffer, Cingulate Chairman and CEO, Provides Update on CTx-1301 in Interview with Innovators with Jane King
2026-11-10 13:00 · Yahoo
Shane Schaffer, Cingulate Chairman & CEO to Present “SMART Launch” Approach at Indegene Digital Summit: Rethinking Commercialization for Emerging Pharma
2026-09-17 12:05 · Yahoo
CING: Second Quarter Results
2026-08-19 15:13 · Yahoo
Cingulate Inc. Reports Second Quarter 2026 Financial Results and Provides Update on CTx-1301 CMC Progress Towards NDA Resubmission and Commercial Readiness
2026-08-13 12:30 · Yahoo
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
2026-08-11 12:30 · Yahoo
Cingulate Announces Publication of Phase 3 ADHD Trial Results in Journal of Child and Adolescent Psychopharmacology
2026-07-30 12:30 · Yahoo
Cingulate Inc. (NASDAQ: CING) Added to Russell 3000E®
2026-07-02 12:30 · Yahoo
Stonegate Capital Partners Updates Coverage on Cingulate Inc. (CING) 1Q26
2026-06-04 20:48 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.